Question-and-Answer SessionEdward NashCanaccord Genuity Corp., Research DivisionSo from at least in the biotech world, we usually -- I would say Madrigal doesn't need any introductions because they were the company that got the first drug approved for a very large indication out there known as MASH. You've had a really impressive second quarter and with continued strong growth. Although the company does not provide specific revenue guidance, could you maybe talk to us a little bit about the commercial growth of Rezdiffra since its launch in April of '24? And how Madrigal positions Rezdiffra from a perspective of the long-term expectations?